AHA Coding Clinic® for ICD-10-CM and ICD-10-PCS - 2021 Issue 4; ICD-10-CM New/Revised Codes
Immune Effector Cell-Associated Neurotoxicity Syndrome
Code G92, Toxic encephalopathy, has been expanded based on the American Society for Transplantation and Cellular Therapy (ASTCT) scale. This expansion also includes codes that describe other and unspecified toxic encephalopathy. The new codes are as follows:G92.00, Immune effector cell-associated neurotoxicity syndrome, grade unspecified G92.01, Immune effector cell-associated neurotoxicity syndrome, grade 1 G92.02, Immune effector cell-associated neurotoxicity syndrome, grade 2 G92.03, Immune effector cell-associated neurotoxicity syndrome, grade 3 G92.04, Immune effector cell-associated neurotoxicity syndrome, grade 4 G92.05, Immune effector cell-associated neurotoxicity syndrome, grade 5 G92.8, Other toxic encephalopathy G92.9, Unspecified toxic...
Subscribe or sign in to view the full article.
Article Overview
This article reviews an ICD-10-CM expansion tied to immune effector cell-associated neurotoxicity syndrome and the ASTCT grading framework used in related clinical documentation. It discusses the broader clinical context of CAR T-cell therapy, associated neurologic manifestations, and how the update fits into coding for toxic encephalopathy and related conditions. The piece is relevant for medical coders, CDI specialists, and billing teams working with oncology, hematology, and transplant-related records.
Why This Topic Matters
The update affects how documentation related to immune effector cell-associated neurotoxicity syndrome is captured in ICD-10-CM and highlights the importance of clear provider grading and associated condition documentation. It is useful for organizations that code adverse neurologic effects in immunotherapy and need to stay aligned with current classification changes.
Article Sections
-
ICD-10-CM update for toxic encephalopathy and ICANS
Introduces the code family expansion and identifies the clinical area affected by the update. It frames the article as a coding-focused overview of immune effector cell-associated neurotoxicity syndrome.
-
Clinical background and related therapy context
Summarizes the neurologic syndrome in the setting of immune therapies, including the general clinical scenarios where it may appear. It also places the topic alongside related treatment-associated complications.
-
ASTCT grading framework and documentation considerations
Describes the consensus grading approach used in the clinical setting and the types of assessment factors involved. It also addresses the importance of provider documentation for assigning the correct level of specificity.
-
Coding guidance and associated conditions
Covers broad coding instructions related to the condition, including sequencing and the need to capture additional documented signs and symptoms. It emphasizes the coding context without reproducing rule details.
What You Will Learn
- The ICD-10-CM code family affected by the update
- The clinical context in which immune effector cell-associated neurotoxicity syndrome occurs
- How ASTCT grading is discussed in relation to documentation
- The broader categories of associated findings and documentation considerations addressed in the article
Who Should Read This
- Medical coders
- Coding auditors
- Clinical documentation integrity specialists
- Revenue cycle staff
- Oncology and hematology billing teams
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com